På sit møde i juli 2007 fandt CHMP på baggrund af alle forelagte oplysninger og den faglige drøftelse i udvalget, at benefit/ risk- forholdet er gunstigt for Fentanyl- ratiopharm 25/ 50/ 75/ 100 µg/ h Matrixpflaster og tilknyttede navne, at de af Frankrig rejste indvendinger ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During their July 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Fentanyl- ratiopharm 25/ 50/ 75/ 100 µg/ h Matrixpflaster and associated names, that the objections raised by France should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.